Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models

Clinical Biochemistry

Volumn 37, Issue 5, 2004, Pages 333-343

  Boffa, Michael B ^a   Marcovina, Santica M ^b   Koschinsky, Marlys L ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Animal models; Apolipoprotein(a); Atherosclerosis; Kringles; Lipoprotein(a); Thrombosis; Transgenics

Indexed keywords

APOLIPOPROTEIN B; DISULFIDE; FIBRIN; FIBRINOGEN; FIBRONECTIN; GLYCOSAMINOGLYCAN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPONTIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

AMINO ACID SEQUENCE; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COVALENT BOND; DNA MICROARRAY; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; GEL FILTRATION CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; META ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; PATHOGENICITY; PERIPHERAL VASCULAR DISEASE; PLASMINOGEN ACTIVATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STROKE; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSGENIC MOUSE; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOLIPOPROTEINS; APOPROTEIN(A); ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); MICE; MICE, TRANSGENIC; MODELS, ANIMAL; RABBITS; RISK FACTORS; THROMBOSIS;

EID: 1842829035     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2003.12.007     Document Type: Review

References (82)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol. Microbiol. Scand. 59:1963;362-382.
2. McLean J.W., Tomlinson J.E., Kuang W.-J.et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
3. Lawn R.M. How often has Lp(a) evolved? Clin. Genet. 49:1996;167-174.
4. Executive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J. Am. Med. Assoc. 285:2001;2486-2497.
5. Marcovina S.M., Koschinsky M.L. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin. Vasc. Med. 2:2002;335-344.
6. Marcovina S.M., Koschinsky M.L. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr. Opin. Lipidol. 14:2003;361-366.
7. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 102:2000;1082-1085.
8. Glader C.A., Birgander L.S., Stenlund H., Dahlen G.H. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J. Intern. Med. 252:2002;27-35.
9. Armstrong V.W., Cremer P., Eberle E.et al. The association between serum Lp(a) concentrations and angiographically-assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 62:1986;249-257.
10. Maher V.M., Brown B.G., Marcovina S.M., Hillger L.A., Zhao X.Q.et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 274:1995;1771-1774.
11. Hopkins P.N., Wu L.L., Hunt S.C., James B.C., Vincent G.M., Williams R.R. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;2783-2792.
12. Kronenberg F., Kronenberg M.F., Kiechl S.et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 100:1999;1154-1160.
13. von Eckardstein A., Schulte H., Cullen P., Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J. Am. Coll. Cardiol. 37:2001;434-439.
14. Koschinsky M.L., Côté G.P., Gabel B.R., van der Hoek Y.Y. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J. Biol. Chem. 268:1993;19819-19825.
15. Albers J.J., Kennedy H., Marcovina S.M. Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: evaluation of amino acid analysis data. J. Lipid Res. 37:1996;192-196.
16. Gabel B.R., Koschinsky M.L. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry. 34:1995;15777-15784.
17. Marcovina S.M., Hobbs H.H., Albers J.J. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin. Chem. 42:1996;436-439.
18. van der Hoek Y.Y., Wittekoek M.E., Beisiegel U., Kastelein J.J., Koschinsky M.L. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms. Hum. Mol. Genet. 2:1993;361-366.
19. Lackner C., Cohen J.C., Hobbs H.H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum. Mol. Genet. 2:1993;933-940.
20. Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80:1987;458-465.
21. Gabel B.R., May L.F., Marcovina S.M., Koschinsky M.L. Lipoprotein(a) assembly. Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation. Arterioscler. Thromb. Vasc. Biol. 16:1996;1559-1567.
22. Ernst A., Helmhold M., Brunner C., Petho-Schramm A., Armstrong V.W., Muller H.J. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J. Biol. Chem. 270:1994;6227-6234.
23. Gabel B.R., Koschinsky M.L. Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry. 37:1998;7892-7898.
24. Becker L., McLeod R.S., Marcovina S.M., Yao Z., Koschinsky M.L. Identification of a critical lysine residue in apolipoproteinB-100 that mediates noncovalent interaction with apolipoprotein(a). J. Biol. Chem. 276:2001;36155-36162.
25. Rahman M., Jia Z., Gabel B.R., Marcovina S.M., Koschinsky M.L. Expression of apolipoprotein(a) kringle IV type 9 in Escherichia coli: demonstration of a specific interaction between kringle IV type 9 and apolipoproteinB-100. Protein Eng. 11:1998;1249-1256.
26. Marcovina S.M., Koschinsky M.L., Albers J.J., Skarlatos S. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin. Chem. 49:2003;1785-1796.
27. Marcovina S.M., Albers J.J., Gabel B., Koschinsky M.L., Gaur V.P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin. Chem. 41:1995;246-255.
28. Edelstein C., Hinman J., Marcovina S., Scanu A.M. Properties of human free apolipoprotein(a) and lipoprotein(a) after either freezing or lyophilization in the presence and absence of cryopreservatives. Anal. Biochem. 288:2001;201-208.
29. Marcovina S.M., Zhang Z.H., Gaur V.P., Albers J.J. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem. Biophys. Res. Commun. 191:1993;1192-1196.
30. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H.J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 9:1989;579-592.
31. Dangas G., Mehran R., Harpel P.C.et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J. Am. Coll. Cardiol. 32:1998;2035-2042.
32. Carmeliet P., Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin. Thromb. Hemost. 22:1996;525-542.
33. Sangrar W., Bajzar L., Nesheim M.E., Koschinsky M.L. The antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry. 34:1995;5151-5157.
34. Rand M.L., Sangrar W., Hancock M.A.et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide, SFLLRN. Arterioscler. Thromb. Vasc. Biol. 18:1998;1393-1399.
35. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachman R.L. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J. Biol. Chem. 266:1991;2459-2465.
36. Li X.N., Grenett H.E., Benza R.L.et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;3215-3223.
37. Buechler C., Ullrich H., Ritter M.et al. Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood. 97:2001;981-986.
38. Kojima S., Harpel P.C., Rifkin D.B. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113:1991;1439-1445.
39. Grainger D.J., Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L., Wade D.P., Lawn R.M. The proliferation of human smooth muscle cells is promoted by lipoprotein(a). Science. 260:1993;1655-1658.
40. Desmarais R.L., Sarembock I.J., Ayers C.R., Vernon S.M., Powers E.R., Gimple L.W. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 91:1995;1403-1409.
41. Miyata M., Biro S., Arima S.et al. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am. Heart J. 130:1996;269-273.
42. Adams M.R., Kinlay S., Blake G.J., Orford J.L., Ganz P., Selwyn A.P. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic disorders. Annu. Rev. Med. 51:2000;149-167.
43. Haque N., Zhang X., French D.L.et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation. 102:2000;786-792.
44. Allen S., Khan S., Tam S., Koschinsky M., Taylor P., Yacoub M. Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. FASEB J. 12:1998;1765-1766.
45. Zhao S.P., Xu D.Y. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb. Res. 100:2000;501-510.
46. Takami S., Yamashita S., Kihara S.et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 97:1998;721-728.
47. Zhao S.P., Xu D.Y. Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells. Clin. Chim. Acta. 296:2000;121-133.
48. Galle J., Schneider R., Heinloth A.et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int. 55:1999;1450-1461.
49. Schachinger V., Halle M., Minners J. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J. Am. Coll. Cardiol. 30:1997;927-934.
50. Moeslinger T., Friedl R., Volf I., Brunner M., Koller E., Spieckermann P.G. Inhibition of inducible nitric oxide synthesis by oxidized lipoprotein(a) in a murine macrophage cell line. FEBS Lett. 478:2000;95-99.
51. Pellegrino M., Furmaniak-Kazmierczk E., Cao K.et al. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J. Biol. Chem. 23:2004;61A. in press.
52. Lawn R.M., Boonmark N.W., Schwartz K.et al. The recurring evolution of lipoprotein(a). Insights from cloning hedgehog apolipoprotein(a). J. Biol. Chem. 270:1995;24004-24009.
53. Lawn R.M., Wade D.P., Hammer R.E., Chiesa G., Verstuyft J.G., Rubin E.M. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 360:1992;670-672.
54. Fan J., Araki M., Wu L.et al. Assembly of lipoprotein(a) in transgenic rabbits expressing human apolipoprotein(a). Biochem. Biophys. Res. Commun. 255:1999;639-644.
55. Frazer K.A., Narla G., Zhang J.L., Rubin E.M. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat. Genet. 9:1995;424-431.
56. Zysow B.R., Kauser K., Lawn R.M., Rubanyi G.M. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 17:1997;1741-1745.
57. Rouy D., Duverger N., Lin S.D.et al. Apolipoprotein(a) yeast artificial chromosome transgenic rabbits. Lipoprotein(a) assembly with human and rabbit apolipoprotein B. J. Biol. Chem. 273:1998;1247-1251.
58. Mooser V., Berger M.M., Tappy L.et al. Major reduction in plasma Lp(a) levels during sepsis and burns. Arterioscler. Thromb. Vasc. Biol. 20:2000;1137-1142.
59. Chiesa G., Hobbs H.H., Koschinsky M.L., Lawn R.M., Maika S.D., Hammer R.E. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J. Biol. Chem. 267:1992;24369-24374.
60. Callow M.J., Stoltzfus L.J., Lawn R.M., Rubin E.M. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 91:1994;2130-2134.
61. Cheesman E.J., Sharp R.J., Zlot C.H.et al. An analysis of the interaction between mouse apolipoprotein B-100 and apolipoprotein(a). J. Biol. Chem. 275:2000;28195-28200.
62. Callow M.J., Verstufyt J., Tangirala R., Palinski W., Rubin E.M. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein(a). J. Clin. Invest. 96:1995;1639-1646.
63. Liu A.C., Lawn R.M., Verstuyft J.G., Rubin E.M. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. J. Lipid Res. 35:1994;2263-2267.
64. Mancini F.P., Newland D.L., Mooser V.et al. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler. Thromb. Vasc. Biol. 15:1995;1911-1916.
65. Sanan D.A., Newland D.L., Tao R.et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc. Natl. Acad. Sci. U. S. A. 95:1998;4544-4549.
66. Berg K., Svindland A., Smith A.J.et al. Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet. Atherosclerosis. 163:2002;99-104.
67. Brousseau M.E., Hoeg J.M. Transgenic rabbits as models for atherosclerosis research. J. Lipid Res. 40:1999;365-375.
68. van der Hoek Y.Y., Kastelein J.J., Koschinsky M.L. Analysis of structure-function relationships in human apolipoprotein(a). Can. J. Physiol. Pharmacol. 72:1994;304-310.
69. Sun H., Unoki H., Wang X.et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J. Biol. Chem. 277:2002;47486-47492.
70. Guevara J. Jr., Spurlino J., Jan A.Y.et al. Proposed mechanisms for binding of apo[a] kringle type 9 to apo B-100 in human lipoprotein[a]. Biophys. J. 64:1993;686-700.
71. Fan J., Challah M., Shimoyamada H., Siomi M., Marcovina S., Watanabe T. Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein[a]. J. Lipid Res. 41:2000;1004-1012.
72. Rader D.J., Mann W.A., Cain W.et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J. Clin. Invest. 95:1995;1403-1408.
73. Fan J., Shimoyamada H., Sun H., Marcovina S., Honda K., Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesion in response to a cholesterol-rich diet. Arterioscler. Thromb. Vasc. Biol. 21:2001;88-94.
74. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis. 36:1980;261-268.
75. Grainger D.J., Kemp P.R., Liu A.C., Lawn R.M., Metcalfe J.C. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 370:1994;460-462.
76. Palabrica T.M., Liu A.C., Aronovitz M.J., Furie B., Lawn R.M., Furie B.C. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat. Med. 1:1995;256-259.
77. Biemond B.J., Friederich P.W., Koschinsky M.L.et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation. 96:1997;1612-1615.
78. Dagdelen S., Eren N., Akdemir I., Karabulut H., Ergelen M., Caglar N. The effect of lipoprotein-a on thrombolytic therapy and spontaneous reperfusion in acute myocardial infarction. A comparative study. Int. Angiol. 21:2002;384-389.
79. Moliterno D.J., Lange R.A., Meidell R.S.et al. Relation of plasma lipoprotein(a) to infarct patency in survivors of myocardial infarction. Circulation. 88:1993;935-940.
80. Boonmark N.W., Lou X.J., Yang Z.J.et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J. Clin. Invest. 100:1997;558-564.
81. Hughes S.D., Lou X.J., Ighani S.et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J. Clin. Invest. 100:1997;1493-1500.
82. Lou X.J., Boonmark N.W., Horrigan F.T., Degen J.L., Lawn R.M. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;12591-12595.